From a chemical blueprint for protein production to an off-the-shelf therapeutic

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 265-274

  Van Lint, Sandra ^a   Heirman, Carlo ^a   Thielemans, Kris ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cancer; Dendritic cell; Immunotherapy; Mrna

Indexed keywords

ALPHA2B INTERFERON; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; KEYHOLE LIMPET HEMOCYANIN; MESSENGER RNA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL PRODUCT; CANCER VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; BRAIN CANCER; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; DENDRITIC CELL; EX VIVO GENE TRANSFER; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REVIEW; TUMOR IMMUNITY; DRUG DEVELOPMENT; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; TRENDS;

BIOLOGICAL PRODUCTS; CANCER VACCINES; DENDRITIC CELLS; DRUG DISCOVERY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RNA, MESSENGER;

EID: 84874724470     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22661     Document Type: Review

References (129)

1. Kreiter S, Diken M, Selmi A, Tureci O, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 2011 23:399-406; PMID:21497074; http://dx.doi.org/10.1016/j.coi.2011.03.007.
2. Van Lint S, Thielemans K, Breckpot K. mRNA: delivering an antitumor message? Immunotherapy 2011 3 605-7 PMID:21554090 http://dx.doi.org/10.2217/imt. 11.28.
3. Pascolo S. Vaccination with messenger RNA. Methods Mol Med 2006
4. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004; 4:1285-94; PMID:15268662; http://dx.doi.org/10.1517/14712598.4.8.1285. (Pubitemid 39005734)
5. Bringmann A, Held SA, Heine A, Brossart P. RNA vaccines in cancer treatment. J Biomed Biotechnol 2010; 2010:623687; PMID:20625504; http://dx.doi.org/10.1155/2010/623687.
6. Kuhn AN, Beiert T, Simon P, Vallazza B, Buck J, Davies BP, et al. mRNA as a versatile tool for exogenous protein expression. Curr Gene Ther 2012 In press: PMID:22827224.
7. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 2012; 30:4414-8; PMID:22546329; http://dx.doi.org/10.1016/j.vaccine. 2012.04.060.
8. Van Lint S, Van Nuffel AMT, Wilgenhof S, Benteyn D, Pen J, Escors D, et al. Priming of Cytotoxic T lymphocyte Responses by Dendritic Cells: Induction of Potent Anti-Tumor Immune Responses. Cytotoxic T Lymphocytes: Mechanisms, Development and Disease. Nova Science Publishers, In press.
9. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004; 6:1175-88; PMID:15468193; http://dx.doi.org/10.1002/jgm.615.
10. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; http://dx.doi.org/10.1146/ annurev-immunol-100311-102839.
11. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199:251-63; PMID:15233739; http://dx.doi.org/10.1111/j. 0105-2896.2004.00139.x. (Pubitemid 38744521)
12. Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787-97; PMID:12189529; http://dx.doi.org/10.1038/sj.cgt.7700499. (Pubitemid 34971310)
13. Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002; 264:135-51; PMID:12191517; http://dx.doi.org/10.1016/S0022-1759(02)00099-6. (Pubitemid 34615899)
14. Tuyaerts S, Michiels A, Corthals J, Bonehill A, Heirman C, de Greef C, et al. Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther 2003; 10:696-706; PMID:12944989; http://dx.doi.org/10.1038/sj.cgt.7700622. (Pubitemid 37129457)
15. Michiels A, Tuyaerts S, Bonehill A, Heirman C, Corthals J, Thielemans K. Delivery of tumor-Antigen-encoding mRNA into dendritic cells for vaccination. Methods Mol Biol 2008; 423:155-63; PMID:18370196; http://dx.doi.org/10.1007/978- 1-59745-194-9-10.
16. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005; 12:772-82; PMID:15750615; http://dx.doi.org/10.1038/sj.gt.3302471. (Pubitemid 40668416)
17. Dullaers M, Breckpot K, Van Meirvenne S, Bonehill A, Tuyaerts S, Michiels A, et al. Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol Ther 2004; 10:768-79; PMID:15451461; http://dx.doi.org/10.1016/j. ymthe.2004.07.017. (Pubitemid 39272866)
18. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108:4009-17; PMID:16940422; http://dx.doi.org/10.1182/blood-2006-04-015024. (Pubitemid 44913269)
19. Fath S, Bauer AP, Liss M, Spriestersbach A, Maertens B, Hahn P, et al. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One 2011; 6:e17596; PMID:21408612; http://dx.doi.org/10.1371/journal.pone.0017596.
20. Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 2012; 20:1063-74; PMID:22371843; http://dx.doi.org/10.1038/mt.2012.11.
21. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60:809-18; PMID:21365467; http://dx.doi.org/10.1007/s00262- 011-0991-9.
22. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, et al. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-Associated invariant chain peptide. Cancer Res 2003 (Pubitemid 37139882)
23. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, et al. Messenger RNAelectroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004 (Pubitemid 38669100)
24. Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet JG, et al. Induction of virusspecific cytotoxic T lymphocytes in vivo by liposomeentrapped mRNA. Eur J Immunol 1993; 23:1719-22; PMID:8325342; http://dx.doi.org/10.1002/ eji.1830230749. (Pubitemid 23218089)
25. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-4; PMID:1545867; http://dx.doi.org/10.1038/356152a0.
26. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002 (Pubitemid 34141815)
27. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003 (Pubitemid 36538616)
28. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigenpresenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72; PMID:8760800; http://dx.doi.org/10.1084/jem.184.2.465. (Pubitemid 26324100)
29. Grunebach F, Muller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003; 10:367-74; PMID:12601391; http://dx.doi.org/10.1038/sj.gt.3301901. (Pubitemid 36372444)
30. De Temmerman ML, Dewitte H, Vandenbroucke RE, Lucas B, Libert C, Demeester J, et al. mRNA-Lipoplex loaded microbubble contrast agents for ultrasoundassisted transfection of dendritic cells. Biomaterials 2011; 32:9128-35; PMID:21868088; http://dx.doi.org/10.1016/j.biomaterials.2011.08.024.
31. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21:341-9; PMID:12901279; http://dx.doi.org/10.1081/CNV-120018224. (Pubitemid 37055665)
32. Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, et al. Epitope and HLAtype independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 2012; 377:23-36; PMID:22269772; http://dx.doi.org/10.1016/j.jim. 2011.12.010.
33. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/ pnas.1008051107.
34. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:15122249; http://dx.doi.org/10.1038/nm1039. (Pubitemid 38667904)
35. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008 66 118-34 PMID:18262431 http://dx.doi.org/10.1016/j. critrevonc.2007.12.007.
36. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118-42; PMID:17850486; http://dx.doi.org/10.1111/j.1600-065X.2007.00551.x. (Pubitemid 47393528)
37. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56:1513-37; PMID:17503040; http://dx.doi.org/10.1007/s00262-007-0334-z. (Pubitemid 47094397)
38. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010; 59:1573-82; PMID:20204387; http://dx.doi.org/10.1007/s00262- 010-0833-1.
39. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol 2005; 35:2452-8; PMID:15997468; http://dx.doi.org/10.1002/eji.200526069. (Pubitemid 41179766)
40. Yoneyama H, Matsuno K, Toda E, Nishiwaki T, Matsuo N, Nakano A, et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 2005; 202:425-35; PMID:16061729; http://dx.doi.org/10.1084/jem.20041961. (Pubitemid 41126960)
41. Schettini J, Mukherjee P. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity. Clin Dev Immunol 2008; 2008:106321; PMID:19190769; http://dx.doi.org/10.1155/2008/106321.
42. Wenner CA, Guler ML, Macatonia SE, O'Garra A, Murphy KM. Roles of IFN-gamma and IFN-Alpha in IL-12-induced T helper cell-1 development. J Immunol 1996
43. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33:1052-62; PMID:12672071; http://dx.doi.org/10.1002/eji.200323676. (Pubitemid 36546693)
44. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003 (Pubitemid 37255200)
45. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-74; PMID:15569976; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684. (Pubitemid 39561754)
46. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-Activated inflammatory dendritic cells. J Exp Med 2007; 204:1441-51; PMID:17535975; http://dx.doi.org/10.1084/jem.20070021. (Pubitemid 46919881)
47. Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen presenting-And tumoricidalcapacities. Blood 2012
48. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001 (Pubitemid 32391565)
49. Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 2004; 6:236-46; PMID:15279716; http://dx.doi.org/10.1215/S1152851703000668. (Pubitemid 39136507)
50. Caruso DA, Orme LM, Amor GM, Neale AM, Radcliff FJ, Downie P, et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005; 103:1280-91; PMID:15693021; http://dx.doi.org/10.1002/cncr.20911. (Pubitemid 40328101)
51. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005 (Pubitemid 40354093)
52. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947. (Pubitemid 43121851)
53. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005; 93:749-56; PMID:16136047; http://dx.doi.org/10.1038/sj.bjc.6602761. (Pubitemid 41486433)
54. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006; 13:905-18; PMID:16710345; http://dx.doi.org/10.1038/sj.cgt.7700961. (Pubitemid 44373791)
55. Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, et al. T cell responses in melanoma patients after vaccination with tumormRNA transfected dendritic cells. Cancer Immunol Immunother 2007; 56:659-75; PMID:16947019; http://dx.doi.org/10.1007/s00262-006-0222-y. (Pubitemid 46348735)
56. Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011; 34:448-56; PMID:21577140; http://dx.doi.org/10.1097/CJI.0b013e31821dcb31.
57. Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, et al. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012; 61:1033-43; PMID:22159452; http://dx.doi.org/10.1007/s00262-011-1176-2.
58. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, et al. Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368.
59. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001; 93:243-51; PMID:11410873; http://dx.doi.org/10.1002/ijc.1323. (Pubitemid 32574281)
60. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003 (Pubitemid 37413557)
61. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002; 99:351-8; PMID:11773639; http://dx.doi.org/10.1073/pnas.231606698. (Pubitemid 34060366)
62. Lutz MB, Schuler G (Pubitemid 35015188)
63. Cools N, Van Tendeloo VF, Smits EL, Lenjou M, Nijs G, Van Bockstaele DR, et al. Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells. J Cell Mol Med 2008; 12:690-700; PMID:18419605; http://dx.doi.org/10.1111/j.1582-4934.2007.00084.x. (Pubitemid 351555146)
64. Enk AH. Dendritic cells in tolerance induction. Immunol Lett 2005; 99:8-11; PMID:15894104; http://dx.doi.org/10.1016/j.imlet.2005.01.011. (Pubitemid 40718926)
65. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27:3135-42; PMID:9464798; http://dx.doi.org/10.1002/eji. 1830271209. (Pubitemid 28018007)
66. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocytederived dendritic cells. Blood 2002; 100:1354-61; PMID:12149218; http://dx.doi.org/10. 1182/blood-2001-11-0017. (Pubitemid 34864292)
67. Kali?ski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001; 97:3466-9; PMID:11369638; http://dx.doi.org/10.1182/blood.V97.11.3466.
68. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006; 108:2655-61; PMID:16763205; http://dx.doi.org/10.1182/blood-2006-03- 011353.
69. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64:5934-7; PMID:15342370; http://dx.doi.org/10.1158/0008-5472.CAN-04-1261. (Pubitemid 39129387)
70. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6:769-76; PMID:15995707; http://dx.doi.org/10.1038/ni1223. (Pubitemid 43090462)
71. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5:508-15; PMID:15064759; http://dx.doi.org/10.1038/ni1059. (Pubitemid 38660463)
72. Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C, et al. Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther 2006; 13:1027-36; PMID:16511519; http://dx.doi.org/10.1038/sj.gt.3302750. (Pubitemid 43905855)
73. Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008; 16:1170-80; PMID:18431362; http://dx.doi.org/10.1038/mt. 2008.77. (Pubitemid 351737084)
74. Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, Francois V, et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009; 15:3366-75; PMID:19417017; http://dx.doi.org/10.1158/ 1078-0432.CCR-08-2982.
75. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000 (Pubitemid 30456456)
76. Cisco RM, Abdel-Wahab Z, Dannull J, Nair S, Tyler DS, Gilboa E, et al. Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol 2004 (Pubitemid 38669160)
77. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17:275-81; PMID:15886117; http://dx.doi.org/10.1016/j.coi.2005.04.004. (Pubitemid 40692662)
78. Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, et al. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012; 61:1033-43; PMID:22159452; http://dx.doi.org/10.1007/s00262-011-1176-2.
79. Wilgenhof S, Pierret L, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, et al. Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases. Melanoma Res 2011; 21:152-9; PMID:21317818; http://dx.doi.org/10.1097/CMR.0b013e328343ece0.
80. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999 (Pubitemid 29334488)
81. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999 (Pubitemid 29062955)
82. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009; 15:2531-40; PMID:19318472; http://dx.doi.org/10.1158/1078-0432. CCR-08-2729.
83. Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EH, Scharenborg N, de Boer A, et al. In situ expression of tumor antigens by messenger RNAelectroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 2009; 69:2927-34; PMID:19318559; http://dx.doi.org/10.1158/0008-5472.CAN-08- 3920.
84. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17:5725-35; PMID:21771874; http://dx.doi.org/10.1158/1078-0432. CCR-11-1261.
85. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; http://dx.doi.org/10.1126/science. 1690918.
86. Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995
87. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588. (Pubitemid 28155090)
88. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose-And time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997; 156:199-209; PMID:9176709; ht tp: //dx.doi.org/10.1111/j.1600-065X.1997. tb00969.x. (Pubitemid 27197203)
89. de Heusch M, Blocklet D, Egrise D, Hauquier B, Vermeersch M, Goldman S, et al. Bidirectional MHC molecule exchange between migratory and resident dendritic cells. J Leukoc Biol 2007; 82:861-8; PMID:17634280; http://dx.doi.org/10.1189/jlb.0307167. (Pubitemid 47511046)
90. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002; 195:1289-302; PMID:12021309; http://dx.doi.org/10.1084/ jem.20020161. (Pubitemid 34564331)
91. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192:1685-96; PMID:11120766; http://dx.doi.org/10.1084/jem.192.12.1685.
92. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001 (Pubitemid 32224894)
93. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 2003 (Pubitemid 36302151)
94. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010; 70:9031-40; PMID:21045153; http://dx.doi.org/10.1158/0008-5472.CAN-10-0699.
95. Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012; 72:1661-71; PMID:22337996; http://dx.doi.org/10.1158/0008-5472. CAN-11-2957.
96. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997 158:4591-601; PMID:9144471. (Pubitemid 127483777)
97. Warren TL, Weiner GJ. Uses of granulocytemacrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000; 7:168-73; PMID:10786654; http://dx.doi.org/10.1097/00062752-200005000-00007. (Pubitemid 30213150)
98. Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Husemann Y, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res 2011; 71:6132-42; PMID:21816907; http://dx.doi.org/10.1158/0008-5472.CAN-11- 0291.
99. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30:1-7; PMID:10602021; http://dx.doi.org/10.1002/1521-4141(200001)30:11: :AIDIMMU1 3.0.CO;2-#. 100. (Pubitemid 30011760)
100. Granstein RD, Ding W,, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA J Invest Dermatol 2000 114 632-6 PMID:10733665 http://dx.doi.org/10.1046/j. 1523-1747.2000.00929.x. (Pubitemid 30226992)
101. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61:2418-24; PMID:15378210; http://dx.doi.org/10.1007/s00018-004-4255-0. (Pubitemid 39382031)
102. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006; 36:2807-16; PMID:17013976; http://dx.doi.org/10.1002/eji.200635910. (Pubitemid 44608463)
103. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojki?-Zrna S, Probst J, et al. Messenger RNAbased vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011; 34:1-15; PMID:21150709; http://dx.doi.org/10.1097/CJI.0b013e3181f7dbe8.
104. Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Husemann Y, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res 2011; 71:6132-42; PMID:21816907; http://dx.doi.org/10.1158/0008-5472.CAN-11- 0291.
105. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23:165-75; PMID:16111635; http://dx.doi.org/10.1016/j.immuni.2005.06.008. (Pubitemid 41169286)
106. Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004; 34:537-47; PMID:14768059; http://dx.doi.org/10.1002/eji.200324198. (Pubitemid 39255964)
107. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, et al. Toll-like receptor-dependent activation of several human blood cell types by protaminecondensed mRNA. Eur J Immunol 2005; 35:1557-66; PMID:15832293; http://dx.doi.org/10.1002/eji.200425656. (Pubitemid 40691436)
108. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31; PMID:14976261; http://dx.doi.org/10.1126/science.1093616. (Pubitemid 38314425)
109. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. doi.org/10.1126/science.1093620. 110. (Pubitemid 38314424)
110. J Biol Chem 2004; 279:12542-50; PMID:14729660; http://dx.doi.org/10.1074/ jbc.M310175200. (Pubitemid 38445825)
111. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8; PMID:11607032; http://dx.doi.org/10.1038/35099560. (Pubitemid 33009951)
112. Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Tureci O, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011; 18:702-8; PMID:21368901; http://dx.doi.org/10.1038/gt.2011.17.
113. Juillard GJ, Boyer PJ. Intralymphatic immunization: current status. Eur J Cancer 1977; 13:439-40; PMID:872860; http://dx.doi.org/10.1016/0014-2964(77) 90099-8. (Pubitemid 8088478)
114. Sigel MB, Sinha YN, VanderLaan WP. Production of antibodies by inoculation into lymph nodes. Methods Enzymol 1983; 93:3-12; PMID:6346012; http://dx.doi.org/10.1016/S0076-6879(83)93031-8. (Pubitemid 13069368)
115. Nilsson BO, Svalander PC, Larsson A. Immunization of mice and rabbits by intrasplenic deposition of nanogram quantities of protein attached to Sepharose beads or nitrocellulose paper strips. J Immunol Methods 1987; 99:67-75; PMID:3571992; http://dx.doi.org/10.1016/0022-1759(87)90033-0. (Pubitemid 17089976)
116. Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM. Intralymphatic injections as a new administration route for allergenspecific immunotherapy. Int Arch Allergy Immunol 2009; 150:59-65; PMID:19339803; http://dx.doi.org/10.1159/000210381.
117. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci U S A 2001; 98:3299-303; PMID:11248073; http://dx.doi.org/10.1073/pnas.051630798. (Pubitemid 32220840)
118. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:537-43; PMID:19680119; http://dx.doi.org/10.1097/ ACI.0b013e3283310ff7.
119. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012; 18:336-41; PMID:22142824; http://dx.doi.org/10.1158/1078-0432. CCR-11-2323.
120. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, et al. Clinical and immunologic effects of intranodal autologous tumor lysatedendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-Alpha2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009; 15:4986-92; PMID:19622576; http://dx.doi.org/10.1158/1078-0432.CCR-08-3240.
121. Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, et al. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol Ther 2010; 18:651-9; PMID:19935776; http://dx.doi.org/10.1038/mt.2009.275.
122. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003; 98:144-54; PMID:12833467; http://dx.doi.org/10. 1002/cncr.11462. (Pubitemid 36741137)
123. Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, Wunderlich JR, et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006; 12:5801-8; PMID:17020987; http://dx.doi.org/10.1158/1078-0432.CCR-05-2421. (Pubitemid 44629612)
124. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31:180-8; PMID:18481387; http://dx.doi.org/10.1097/ CJI.0b013e31815ce501.
125. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler
126. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011; 19:990-9; PMID:21189474; http://dx.doi.org/10.1038/mt.2010.289.
127. Schmidt SM, Haentschel M, Mueller MR. Vaccinations with RNA coding for tumor associated antigens in advanced RCC patients-A phase I/II study. Journal of Clinical Oncology 2008
128. Curevac. Phase I/IIa clinical trialin non-small cell lung cancer (NSCLC) with CV9201, an mRNA based cancer vaccine. 2011; Available from: http://www.curevac. de/pdf/NSCLC-111107-EN.PDF.
129. Kubler H, Maurer T, Stenzl A, Feyerabend S, Steiner U, Schostak M, et al. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-Adjuvanted mRNA. 2011 Available from http://www. curevac.de/pdf/201106-ASCO-PCA-final.pdf.